Atherosclerosis Market

 Market Overview:

The 7 major atherosclerosis markets reached a value of USD 15.0 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 18.8 Billion by 2035, exhibiting a growth rate (CAGR) of 2.04% during 2025-2035.

The atherosclerosis market has been comprehensively analyzed in IMARC's new report titled "Atherosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Atherosclerosis is a chronic disorder characterized by the buildup of plaque inside the arteries. As the disease progresses, it can narrow the artery and impede blood flow, leading to reduced oxygen and nutrient supply to the organs and tissues. This condition can affect any blood vessel within the body, but it most usually occurs in the coronary arteries. The common symptoms associated with the ailment include chest pain or discomfort, heart palpitations, dizziness, shortness of breath, cold sweats, nausea, weakness, lightheadedness, etc. Individuals suffering from this illness may further experience erectile dysfunction, heart attacks, mini-strokes, poor wound healing, etc. Atherosclerosis is typically diagnosed through a combination of medical history, physical examination, and various clinical investigations. During the physical exam, a healthcare provider checks for a weak pulse and other signs indicative of the ailment, such as abnormal sounds (bruits) over the arteries. Several diagnostic procedures and tests, including doppler ultrasound, coronary angiography, cardiac stress tests, etc., are performed to validate the diagnosis. Additionally, blood workups are also conducted to determine the lipid profile of patients, such as levels of total cholesterol and triglycerides.

The rising prevalence of damage or injury to the endothelium on account of high blood pressure, smoking, increased cholesterol levels, inflammation, etc., is primarily driving the atherosclerosis market. In addition to this, the expanding geriatric population, who are prone to plaque formation due to reduced ability of lipid metabolism, is further augmenting the market growth. Moreover, the emerging popularity of effective drugs, such as antihypertensives, statins, anti-platelets, etc., which can respectively control high blood pressure, decrease cholesterol levels, and prevent blood clots, is also creating a positive outlook for the market. Apart from this, the widespread adoption of angioplasty and stenting procedures to treat patients, since they can be performed to open up blocked arteries and improve blood flow, is further bolstering the market growth. Additionally, the escalating utilization of coronary artery bypass grafting for the treatment of advanced disease conditions on account of its numerous benefits, like reduced symptoms of the illness, long-term effectiveness, and enhanced ability to perform daily activities, is expected to drive the atherosclerosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the atherosclerosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for atherosclerosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the atherosclerosis market in any manner.

Key Highlights:

• Atherosclerosis of the arteries is responsible for approximately half of all fatalities in Westernized civilization.
• Persons over 40 have a 50% probability of getting significant atherosclerosis, while the majority of persons over 60 have some atherosclerosis.
• Atherosclerosis is more common in males than women, with 55.4% of men and 45.8% of women having atherosclerotic plaques.
• Every year, more than 450,000 people die suddenly as a result of the atherosclerotic process.
• Atherosclerotic cardiovascular disease affects more than 120 million persons in the United States.

Drugs:

Lescol is recommended for individuals with primary hypercholesterolemia, especially mild variants, and coronary heart disease in order to delay the advancement of coronary atherosclerosis. The prescribed starting dose of lescol is 80mg.

MEDI6570 is a monoclonal antibody that inhibits various ligands for the LOX-1 receptor, including oxidized LDL and other modified lipids. This decreases cytokine release, inhibits monocyte adhesion, and enhances endothelial function to treat atherosclerosis.

RVX 000222 is an orally available small molecule created by Resverlogix Corporation that is being evaluated in clinical trials for the treatment of atherosclerosis and associated cardiovascular disease. RVX000222 targets bromodomain and extra terminal domain (BET) proteins, specifically the BET family member BRD4.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the atherosclerosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the atherosclerosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current atherosclerosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the atherosclerosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the atherosclerosis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the atherosclerosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of atherosclerosis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​​) of atherosclerosis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​​) of atherosclerosis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​​) with atherosclerosis across the seven major markets?
• What is the size of the atherosclerosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of atherosclerosis?
• What will be the growth rate of patients across the seven major markets?
   

Atherosclerosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for atherosclerosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the atherosclerosis market?
• What are the key regulatory events related to the atherosclerosis market?
• What is the structure of clinical trial landscape by status related to the atherosclerosis market?
• What is the structure of clinical trial landscape by phase related to the atherosclerosis market?
• What is the structure of clinical trial landscape by route of administration related to the atherosclerosis market?